Cancer: Preventing collateral damage
In pigs, nitrate supplements can protect salivary glands from the damage caused by radiation therapy to the head and neck.
- Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, United States
Most patients with head and neck cancer will receive radiation therapy in order to kill or shrink their tumor (Alterio et al., 2019). During treatment, physicians try to minimize damage to surrounding, healthy tissues, but off-target doses often harm and kill the sensitive ‘serous acinar cells’ in the salivary parotid gland (Figure 1A). As a result, many patients go on to produce less saliva and develop a persistent dry mouth, also known as xerostomia. This is not a benign condition: people may experience loss of taste, difficulty chewing, swallowing or speaking and, in the long term, tooth and gum decay that can lead to malnutrition (Jensen et al., 2019).
Figure 1
Dietary nitrate initiates a positive feedback that stimulates the growth and survival of serous acinar cells.
(A) The parotid gland (orange), which is a major source of saliva, often becomes damaged when head and neck cancer patients receive radiation therapy (red waves) to kill or shrink their tumors (dark grey). (B) To explore ways to protect this sensitive gland, Feng et al. examined how the nutrient nitrate affected miniature pigs exposed to radiation. This revealed that the animals that do not receive additional nitrate before treatment experience a rapid decrease in salivary flow. Irradiated human parotid cells (top) had decreased levels of sialin (green), a protein that transports nitrates into serous acinar cells (blue rectangle) which produce saliva. As a result, the level of nitrate inside the cell drops, and EGFR (yellow) – one of the components of the EGFR-AKT-MAPK signaling pathway – remains in an inactive state (red dot). This causes the cells to die (apoptosis), perhaps explaining the decline in the flow of saliva in irradiated pigs and humans. Adding inorganic nitrate to the cells before treatment (bottom) increases sialin and therefore nitrate levels inside the cell. In turn, nitrate could increase the production of sialin, creating a positive feedback loop that allows the cell to maintain relatively stable amounts of sialin after radiation. This triggers the activation of EGFR (green dot), which stimulates the cell to grow and prevents programmed cell death.
Few interventions exist to stop this side effect from emerging, aside from technical refinements that limit the exposure of the glands to radiation (Mercadante et al., 2021). Now, in eLife, Songlin Wang and colleagues at Capital Medical University – including Xiaoyu Feng and Zhifang Wu as joint first authors – report a remarkably simple measure that may protect salivary glands during radiation therapy (Feng et al., 2021).
In the body, these glands are an important component of the nitrate cycle, taking up about 25% of the inorganic nitrate present in the blood, concentrating it and then secreting it into the saliva (Lundberg et al., 2018). This nutrient, abundant in leafy greens and many fruits, was once reviled for potentially causing cancer but it is now viewed as a normal component of a healthy diet. It can even help to boost the regeneration of certain heart cells (Lundberg et al., 2018; Marino et al., 2021).
Feng et al. used miniature pigs – whose salivary glands are structurally similar to those of humans – to investigate whether nitrate could help protect against xerostomia after radiation therapy. Animals that were fed daily doses of inorganic nitrate before treatment did not experience a sharp drop in saliva production, and they recovered 80% of their salivary flow within two years.
These benefits were both dose- and time- dependent: higher amounts of supplementary nitrate led to better salivary gland function, but administering the nutrients for the first time two months after treatment yielded minimal results. In the laboratory, adding inorganic nitrate to cells derived from human parotid tissues revealed a similar radioprotective effect. Taken together, these results strongly support supplementing patient’s diets with nitrate to prevent xerostomia.
Exactly how nitrate can protect cells against radiation is not fully understood, but it may involve sialin, a transport protein that helps to usher the nutrient inside serous acinar cells. Feng et al. showed that radiation caused the levels of sialin to rapidly fall. Adding nitrate before treatment, however, boosted the level of sialin, and therefore the amount of the nutrient inside cells. Additional experiments suggest that nitrate then increases the production of sialin, creating a positive feedback loop that activates the EGFR-AKT-MAPK pathway (Figure 1B). This biochemical circuit is known to stimulate cell growth and block programmed cell death (Seshacharyulu et al., 2012). The production of sialin in response to nitrate appeared to be the critical trigger for EGFR activation, which may explain why supplementation was only effective if administered before radiation therapy.
Extrapolating from animal and cell-based models to humans is always uncertain (Mak et al., 2014). Perhaps the most exciting aspect of the work by Feng et al. is that its main conclusion is easy to test, through randomized clinical trials that monitor salivary function (and potentially nitrate levels) before, during and after radiation therapy. This will ultimately help to determine whether nitrate supplementation could offer a low-tech solution to a high-tech problem. If the stunning results presented by Feng et al. translate to humans, this approach may have a major impact on cancer patients experiencing xerostomia.
References
-
Modern radiotherapy for head and neck cancerSeminars in Oncology 46:233–245.https://doi.org/10.1053/j.seminoncol.2019.07.002
-
Lost in translation: animal models and clinical trials in cancer treatmentAmerican Journal of Translational Research 6:114–118.
-
Salivary gland hypofunction and/or xerostomia induced by nonsurgical cancer therapies: ISOO/MASCC/ASCO GuidelineJournal of Clinical Oncology 39:2825–2843.https://doi.org/10.1200/JCO.21.01208
-
Targeting the EGFR signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets 16:15–31.https://doi.org/10.1517/14728222.2011.648617
Article and author information
Author details
Publication history
Copyright
© 2021, Quon and Bunz
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 398
- views
-
- 20
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Cancer: Preventing collateral damage
eLife 10:e74319.
https://doi.org/10.7554/eLife.74319
Further reading
-
- Cell Biology
- Immunology and Inflammation
NLRP3 is an inflammasome seeding pattern recognition receptor activated in response to multiple danger signals which perturb intracellular homeostasis. Electrostatic interactions between the NLRP3 polybasic (PB) region and negatively charged lipids on the trans-Golgi network (TGN) have been proposed to recruit NLRP3 to the TGN. In this study, we demonstrate that membrane association of NLRP3 is critically dependant on S-acylation of a highly conserved cysteine residue (Cys-130), which traps NLRP3 in a dynamic S-acylation cycle at the Golgi, and a series of hydrophobic residues preceding Cys-130 which act in conjunction with the PB region to facilitate Cys-130 dependent Golgi enrichment. Due to segregation from Golgi localised thioesterase enzymes caused by a nigericin induced breakdown in Golgi organisation and function, NLRP3 becomes immobilised on the Golgi through reduced de-acylation of its Cys-130 lipid anchor, suggesting that disruptions in Golgi homeostasis are conveyed to NLRP3 through its acylation state. Thus, our work defines a nigericin sensitive S-acylation cycle that gates access of NLRP3 to the Golgi.
-
- Cell Biology
- Neuroscience
Reactive astrocytes play critical roles in the occurrence of various neurological diseases such as multiple sclerosis. Activation of astrocytes is often accompanied by a glycolysis-dominant metabolic switch. However, the role and molecular mechanism of metabolic reprogramming in activation of astrocytes have not been clarified. Here, we found that PKM2, a rate-limiting enzyme of glycolysis, displayed nuclear translocation in astrocytes of EAE (experimental autoimmune encephalomyelitis) mice, an animal model of multiple sclerosis. Prevention of PKM2 nuclear import by DASA-58 significantly reduced the activation of mice primary astrocytes, which was observed by decreased proliferation, glycolysis and secretion of inflammatory cytokines. Most importantly, we identified the ubiquitination-mediated regulation of PKM2 nuclear import by ubiquitin ligase TRIM21. TRIM21 interacted with PKM2, promoted its nuclear translocation and stimulated its nuclear activity to phosphorylate STAT3, NF-κB and interact with c-myc. Further single-cell RNA sequencing and immunofluorescence staining demonstrated that TRIM21 expression was upregulated in astrocytes of EAE. TRIM21 overexpressing in mice primary astrocytes enhanced PKM2-dependent glycolysis and proliferation, which could be reversed by DASA-58. Moreover, intracerebroventricular injection of a lentiviral vector to knockdown TRIM21 in astrocytes or intraperitoneal injection of TEPP-46, which inhibit the nuclear translocation of PKM2, effectively decreased disease severity, CNS inflammation and demyelination in EAE. Collectively, our study provides novel insights into the pathological function of nuclear glycolytic enzyme PKM2 and ubiquitination-mediated regulatory mechanism that are involved in astrocyte activation. Targeting this axis may be a potential therapeutic strategy for the treatment of astrocyte-involved neurological disease.
